东亚与欧洲人群蛋白质组全基因组研究识别缺血性卒中多个治疗靶点
共定位分析显示10种蛋白中9种(除ABO外)与缺血性卒中共享遗传变异的后验概率≥0.7。这些蛋白中1种无成药性,3种有已知或潜在可重定位药物靶点,6种无任何药物靶点证据。
要点
- 在东亚和欧洲人群中,10种蛋白的遗传预测水平与缺血性卒中显著相关,方向一致。
- 共定位分析为10种蛋白中的9种(除ABO外)与缺血性卒中共享遗传变异提供了强证据(H4后验概率≥0.7)。
- 8种蛋白还因果影响收缩压、LDL-C、BMI、2型糖尿病或房颤,方向符合预期。
核心结论
- 跨 ancestry 的蛋白质组学遗传研究识别出10种蛋白与缺血性卒中存在因果关联,其中若干可能为新型或可重定位的治疗靶点,值得优先进一步研究。
主要发现
- 孟德尔随机化分析中,10种蛋白的遗传预测血浆水平与缺血性卒中显著相关,东亚人群2种、欧洲人群9种,其中6种(FGF5、TMPRSS5、FURIN、F11、ALDH2、ABO)为正相关,4种(GRK5、KIAA0319、PROCR、MMP12)为负相关,方向在东亚与欧洲人群间一致。
- 共定位分析为10种蛋白中的9种(除ABO外)与缺血性卒中共享遗传变异提供了强证据,H4假设后验概率≥0.7。
- 8种蛋白还以预期方向与收缩压(正/负相关:4/2)、低密度脂蛋白胆固醇(1种正相关)、体重指数(1种负相关)、2型糖尿病(2/1)或房颤(3/1)存在因果关联。
- 全表型组关联研究和敲除小鼠模型查询证实了这些蛋白对缺血性卒中或卒中相关性状(如血液学表型)的重要性。
- 10种蛋白中,1种(ABO)无成药性,3种有已知主要(F11)或潜在可重定位(ALDH2、MMP12)的卒中药物靶点,6种(PROCR、GRK5、FGF5、FURIN、KIAA0319、TMPRSS5)无任何药物靶点证据。
关键数值与推荐
- 孟德尔随机化分析中,遗传预测的10种蛋白血浆水平与缺血性卒中的关联在东亚和欧洲人群均显著,方向一致。
- 共定位分析中,9种蛋白(除ABO外)与缺血性卒中共享遗传变异的H4后验概率≥0.7。
- 8种蛋白与收缩压、LDL-C、BMI、2型糖尿病或房颤的因果关联方向符合预期。
- 10种蛋白中,1种无成药性,3种有已知或潜在可重定位药物靶点,6种无药物靶点证据。
临床怎么用
- 研究识别的10种蛋白中,若干可能为新型或可重定位的缺血性卒中治疗靶点,可优先进一步研究。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Analyses of genomic and proteomics data in prospective biobank studies in diverse populations may discover novel or repurposing drug targets for stroke. METHODS: We extracted individual cis-protein quantitative trait locus for 2923 proteins measured using Olink Explore panel from a genome-wide association study in prospective China Kadoorie Biobank and UK Biobank, both established ≈20 years ago. These cis-protein quantitative trait loci were used in ancestry-specific 2-sample Mendelian randomization analyses of ischemic stroke (IS) in East Asians (n=22 664 cases) and Europeans (n=62 100 cases). We further undertook colocalization analyses to examine the shared causal variants of cis-protein quantitative trait locus with stroke, along with various downstream analyses (eg, phenome-wide association study, drug development lookups) to clarify mechanisms of action and druggability. RESULTS: In Mendelian randomization analyses, the genetically predicted plasma levels of 10 proteins were significantly associated with IS in East Asians (n=2) and Europeans (n=9), with 6 proteins (FGF5 [fibroblast growth factor 5], TMPRSS5 [transmembrane protease serine 5], FURIN, F11 [coagulation factor XI], ALDH2 [aldehyde dehydrogenase 2], and ABO [histo-blood group ABO system transferase]) showing positive and 4 (GRK5 [G protein-coupled receptor kinase 5], KIAA0319 [dyslexia-associated protein KIAA0319], PROCR [endothelial protein C receptor], and MMP12 [macrophage metalloelastase 12]) showing inverse associations, all directionally consistent between East Asians and Europeans. Colocalization analyses provided strong evidence (posterior probabilities for the H4 hypothesis ≥0.7) of shared genetic variants with IS for 9 out of 10 proteins (except ABO). Moreover, 8 proteins were also causally associated, in the expected directions, with systolic blood pressure (positive/inverse: 4/2), low-density lipoprotein cholesterol (1 positive), body mass index (1 inverse), type 2 diabetes (2/1), or atrial fibrillation (3/1). Phenome-wide association study analyses and lookups in knock-out mouse models confirmed their importance for IS or stroke-related traits (eg, hematologic phenotypes). Of these 10 proteins, 1 was not druggable (ABO), 3 had known primary (F11) or potentially repurposed (ALDH2, MMP12) drug targets for stroke, and 6 (PROCR, GRK5, FGF5, FURIN, KIAA0319, and TMPRSS5) had no evidence of any drug targets. CONCLUSIONS: Proteogenomic investigation in diverse ancestry populations identified the causal relevance of 10 proteins for IS, with several being potentially novel or repurposed targets that could be prioritized for further investigation.
引用
- Yao P, Mazidi M, Pozarickij A, et al. Proteome-Wide Genetic Study in East Asians and Europeans Identified Multiple Therapeutic Targets for Ischemic Stroke. Stroke. 2025. PMID: 40304040. doi:10.1161/STROKEAHA.125.050982
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。